Scotiabank raises Guardant Health stock price target to $60 on strong results

Published 31/07/2025, 12:58
Scotiabank raises Guardant Health stock price target to $60 on strong results

Investing.com - Scotiabank (TSX:BNS) raised its price target on Guardant Health (NASDAQ:GH) to $60.00 from $57.00 on Thursday, while maintaining a Sector Outperform rating following the company’s second-quarter results. According to InvestingPro data, analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $47 to $70.

The healthcare company beat expectations across the board in its Q2 2025 financial performance, prompting management to raise full-year revenue guidance to 24-25% growth year-over-year, up significantly from the initial 15-16% projection. This builds on the company’s impressive 28.2% revenue growth over the last twelve months, with a robust gross margin of 61.34%.

Guardant Health’s Therapy Selection portfolio, which includes the Guardant360 products, continues to show impressive strength, with the company building a stronger competitive position through its expanding Smart Liquid Biopsy applications and companion liquid biopsy opportunities. With a current ratio of 4.11, InvestingPro analysis shows the company maintains strong liquidity to support its growth initiatives.

The company’s Reveal minimal residual disease (MRD) test is gaining momentum following Medicare reimbursement for colorectal cancer surveillance earlier this year, with further reimbursement and indication expansions expected in the near term.

Guardant’s Shield blood-based colorectal cancer screening test is exceeding expectations in its first commercial year, with Scotiabank noting its multi-cancer detection capability offers a compelling screening platform strategy that differentiates it from competitors. The company, currently valued at $5.6 billion, has seen its stock surge 47.92% year-to-date despite being slightly overvalued according to InvestingPro’s Fair Value model.

In other recent news, Guardant Health Inc. reported impressive financial results for the second quarter of 2025. The company exceeded earnings expectations with an earnings per share (EPS) of -$0.44, significantly better than the projected -$0.72. This resulted in a positive surprise of 38.89%. Revenue for the quarter reached $232.1 million, surpassing the anticipated $211.27 million, marking a 9.86% revenue surprise. These results highlight a strong performance for Guardant Health, as the company managed to outperform analysts’ forecasts. The earnings announcement has been a focal point for investors, reflecting a positive sentiment in the market. The company’s ability to deliver better-than-expected financial results is a notable development for stakeholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.